Menu Back toSafety Compliance

DIA 2021 Global Annual Meeting

Safety Compliance

Session Chair(s)

Alan  Hochberg

Alan Hochberg

  • Principal Scientific Enablement Director, Scientific Enablement and Processes
  • Genentech, A Member of the Roche Group, United States
This session will provide an update on key topics related to compliance with pharmacovigilance regulations, including information on inspection findings and procedures in general and with a specific focus on risk management, as well as the broader compliance implications of Clinical Trial Regulation.
Learning Objective : Examine how a risk-based approach leads to more efficient PV; Identify the systems gaps that have been revealed by inspections; Describe practical ways to globally harmonize PV and GCP compliance; Assess MHRA inspection Metrics and find the prominent areas of the risk management system which lead to critical and major findings.


Mandy  Budwal-Jagait, MSc

MHRA GPvP Inspections: Trends in Compliance and Evolution of Inspections

Mandy Budwal-Jagait, MSc

  • Head of GCP and Lead Senior GCP Inspector
  • Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
Shelley  Gandhi, MSc

Clinical Trial Regulation is an Opportunity to Revisit Compliance at the Pharmacovigilance and GCP Interface

Shelley Gandhi, MSc

  • Strategic Advisor, Pharmacovigilance and Drug Safety
  • NDA Group, United Kingdom
Garima  Mishra, MPharm

Risk Management System: An Area of Specific Concern : Analysis of MHRA GPvP Inspection Metrics Reports from June 2009-March 2020

Garima Mishra, MPharm

  • Subject Matter Expert
  • APCER Life Sciences, India